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ABSTRACT 
Objective: To evaluate the clinical pharmacist role in the prescription analysis, drug interaction and the impact of patient counseling in type 2 
diabetes mellitus patients. 
Methods: A prospective study was conducted in 203 type II Diabetes Mellitus patients for a period of 6 mo in the Diabetology department. 
Prescriptions were analyzed and self-care assessment for good health practices were collected using a questionnaire and the adherence scores were 
calculated. Patient counseling was provided to the patient and a follow up was done using the same self care assessment questionnaire. 
Results: Out of 203 patients, 86 multiple therapy, 68 dual therapy and 49 monotherapy were observed. Glimepiride+Metformin (54), a combination of short 
acting and intermediate-acting insulin (41) was the most commonly prescribed drugs. Out of 1102 drugs, 488 were anti diabetic drugs, 35 were antibiotics, 
579 were other drug classes prescribed. The drug interactions were reported. The adherence score shows a highly significant impact after counseling. 
Conclusion: The results of the current study helps to understand the changes in prescription pattern, drug interactions and the impact of patient 
counseling by a clinical pharmacist. 
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INTRODUCTION 
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by 
the presence of hyperglycemia accompanied by impairment in the 
metabolism of carbohydrates, lipids, and proteins. DM can vary greatly, 
but always include defects in either secretion of insulin or response or 
both at some point in the course of the disease [1]. The prevalence of 
diabetes mellitus (DM) has risen dramatically in adults worldwide from 
6.6% in 2010 and estimated to be 7.8% by 2030, with India contributing 
to the major part Diabetes mellitus, the chronic disease requires 
comprehensive management including pharmacological and non-
pharmacological measures for achieving optimal glycemic control and 
better therapeutic outcomes to enhance the quality of life [2]. 
Patient’s poor knowledge on the disease and its management and 
medication non-adherence lead to inadequate management of 
diabetes. Patient education is the most effective way to improvise 
patient responsibility towards disease management and minimize 
diabetes complications and improve the outcomes. This 
corroborates the importance of awareness among diabetics in DM 
management. Studies have confirmed about the positive influence of 
pharmacist mediated education on knowledge, attitude, and 
practices about disease and therapy, which has shown a positive 
impact on health-related quality of life [3]. 
Medication adherence is defined as the extent to which a patient’s 
medication-taking behaviour coincides with the intention of the 
health advice he or she has been given. It is the most important 
factor that determines therapeutic outcomes, especially in patients 
suffering from a chronic illness like diabetes mellitus. The 
pharmacist can contribute and play a major role in the assessment of 
patients understanding about the illness and the therapy and 
communicate the benefits of treatment and assess the patient’s 
readiness for the care plan and discuss any barriers to adherence 
that patients may have [3]. 
However, the effectiveness of the treatment for diabetes relies upon 
the degree of medication adherence towards the endorsed 
treatment. As per the World Health Organization (WHO), guideline 
adherence is up to, which degree an individual behaviour; following 
a diet, receiving medication, and executing lifestyle changes 
corresponds with recommendations from the health care provider. 
Non-adherence to medication is most basic among patients with 
diabetes. Inadequate adherence compromises safety and prompts 
ineffective treatment, which ascends in mortality and morbidity 
rate. Medication adherence is essential for successful treatment in 
patients with DM results in a better outcome, for example, 
hemoglobin A1C values reduce the risk of hospitalization and 
mortality as well as the health care costs will be diminished.  
The prescription analysis and the patient counseling by a clinical 
pharmacist will provide valuable information regarding the 
prescription trends and provides the physician about the drug 
therapy, which helps to improve the quality of care and decreases 
the healthcare costs. The objective of the study is to evaluate the 
clinical pharmacist role in the prescription analysis, drug interaction 
and the impact of patient counseling in type 2 diabetes mellitus 
patients. 
MATERIALS AND METHODS  
Study design and ethical considerations 
This was a prospective study conducted in the outpatient 
department of a tertiary care hospital after obtaining the approval of 
the institutional ethics committee (REF NO: EC/PHARM D/2019-03). 
• Study site 
The study was conducted in the Endocrinology and Diabetology 
Department. 
• Study population 
203 patients with type 2 Diabetes Mellitus who receive Diabetic 
medication on regular basis in addition to patient counseling. Based 
on Raosoft sample size calculator and previously conducted studies. 
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• Study period 
A prospective study was carried out over a period of six months 
from February 2019 to July 2019. 
• Study criteria 
Inclusion criteria Patients with type 2 Diabetes mellitus of age group 
between 35 to 85 y, Patients of both genders and Patients with co-
morbities. Exclusion criteria: patients with Gestational Diabetes 
Mellitus, patients with Type 1 Diabetes mellitus, Inpatients and 
Patients who are not accepting the consent. 
 Data analysis and interpretation 
The subjects were described in respect of their demographic and 
clinical profiles according to the type of variables such as 
continuous and categorical variables. In respect of continuous 
variables, the averages were used. The interpretations were done 
by student paired “t” test within the subjects. The categorical 
variables were interpreted by Wilcoxon rank sign test. The above 
statistical procedures were performed with the help of the 
statistical package namely IBM SPSS Statistics-20. The values less 
than or equal to 0.05 (P≤0.05) were fixed as statistically 
significant. 
RESULTS 
Out of 203 patients, majority of the study population were male 121 
(59.6%) and female were 82 (40.4%) (table 1). The majority of 
study subjects were from the age group of 55-64 y which is 36.5% of 
the population, followed by 65-74 y (23.6%), 45-54 y(22.2%), 35-44 
y (16.7%) and the least was in the age group of 75-84 y(1%). The 
mean age of total subjects was 55.8±10.4 y with range of 35-84 y 
(table 2). The subjects having the family history were 69 (34.0%) 
and not having the family history were 134 (66%) among the total 
study population (table 3). 
 
Table 1: Gender wise distribution of study subjects (N=203) 
S. No. Gender Frequency Percentage (%) 
1 Male 121 59.6 
2 Female 82 40.4 
Total 203 100.0 
 
Table 2: Description of study subjects according to their Age 
S. No. Age group (years) Frequency Percentage (%) mean±SD 
1 35-44 34 16.7 38.5±2.8 
2 45-54 45 22.2 50.0±2.6 
3 55-64 74 36.5 58.8±3.0 
4 65-74 48 23.6 67.9±2.6 
5 >75 2 1.0 75.5±0.7 
Total 203 100.0 55.8±10.4 
 
Table 3: Family history wise distribution of study subjects (N=203) 
S. No. Family history Frequency Percentage (%) 
1 Patients with Family history 69 34.0 
2 Patients with No family history 134 66.0 
Total 203 100.0 
 
The social history shows that patients having the habit of alcoholism was 
16 (7.9%) and smoking was 12 (5.9%). The remaining 175 (86.2%) of 
subjects were not having any social histories (fig. 1). 72(35.5%) patients 
reported that they have no co-morbidities. The most commonly reported 
co-morbidity was Hypertension 75(36.9%), followed by dyslipidemia 
38(18.7%), coronary artery disease 15(7.4%) and cerebrovascular 
accident 3 (1.5%) (fig. 2). Neuropathy 46 patients (22.7%) was the 
highly observed complication followed by nephropathy 9 patients 
(4.4%) and retinopathy 7 patients (3.4%). 141 patients (69.5%) did not 
have any complications (table 4). 
 
 
Fig. 1: Percentage distribution of social histories 
 
Table 4: Complications of study subjects 
S. No. Complications Frequency % 
1 Neuropathy 46 22.7 
2 Nephropathy 9 4.4 
3 Retinopathy 7 3.4 
4 Nil 141 69.5 
 Total 203 100.0 
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Fig. 2: Percentage distribution of co morbidity 
 
Multiple therapy was the highly followed therapy 86 (42.36%), dual 
therapy was administered to 68 (33.50%) and mono therapy was 
administered to 49 (24.14%) of subjects (fig. 3). The maximum of 
subjects 85(41.3%) have the duration as 1-5 y and the least duration 
was 15-20 y as 19 (9.4%). The total mean duration was 6.6±5.1 y 
(table 5). Glimepiride+Metformin combination 54 was the highly 
prescribed oral hypoglycemic agent followed by Glimepiride 53 
(table 6 and 7). 
 
 
Fig. 3: Percentage of therapy administered 
 
Table 5: Duration of diabetic mellitus 
S. No. Duration of DM (years) Frequency Percentage (%) mean±SD 
1 Below 5 84 41.3 2.3±1.0 
2 5-10 55 27.1 5.8±1.0 
3 10-15 45 22.2 11.0±1.3 
4 15 and above 19 9.4 18.0±2.2 
 Total 203 100.0 6.6±5.1 
 
Table 6: Current drugs administered (single drugs) 
S. No. Drugs Frequency 
1 Glimepiride 53 
2 Metformin 31 
3 Teneligliptin 30 
4 Pioglitazone 29 
5 Vildagliptin 24 
6 Voglibose 23 
7 Gliclazide 18 
8 Empagliflozin 7 
9 Sitagliptin 5 
10 Linagliptin 5 
11 Dapagliflozin 3 
12 Glibenclamide 3 
13 Canaglifloxin 2 
14 Gemigliptin 2 
15 Glipizide 1 
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Table 7: Combinations 
S. No.  Drugs Frequency 
1 Glimepiride+Metformin 54 
2 Gliclazide+Metformin 16 
3 Metformin+Teneligliptin 13 
4 Glimepiride+Metformin+Voglibose 11 
5 Glibenclamide+Metformin 10 
6 Metformin+Vildagliptin 9 
7 Metformin+Sitagliptin 9 
8 Glipizide+Metformin 5 
9 Glimepiride+Metformin+Pioglitazone 4 
10 Metformin+Voglibose 3 
11 Metformin+Saxagliptin 3 
12 Empagliflozin+Linagliptin 2 
13 Glimepiride+Pioglitazone 2 
 
Among the types of insulin used, the combination of short acting and 
intermediate acting insulin (41) was the maximum prescribed and the 
combination of long acting and rapid acting insulin (1) was the least 
prescribed (table 8). The prescription trend were analyzed in 203 
patients. A total of 1102 drugs were prescribed to the type 2 diabetes 
mellitus patients and the average number of drugs per prescription 
was 6 in number. Total number of anti-diabetics out of the total 
number of drugs prescribed was 488 (table 9). The type of severity of 
drug interaction in the study population shows that 32(84.21%) 
moderate interactions were theoretically observed in the prescription, 
5 (13.16%) of minor interactions and 1 (2.63%) of major interaction 
was also noticed. The major drug interactions was found with Tab. 
Glimepiride and Tab. Fluconazole. The moderate drug interaction was 
found between Tab. Pioglitazone and Insulin Glargine (table 10). 
 
Table 8: Types of insulin 
S. No. Types of insulin Frequency 
1 Rapid acting insulin 22 
2 Intermediate acting insulin 9 
3 Long acting insulin 31 
4 Combination of short acting and intermediate acting insulin 41 
5 Combination of rapid acting and intermediate acting insulin 7 
6 Combination of long acting and rapid acting insulin 1 
 
Table 9: Prescription details in diabetes mellitus patients 
Details of prescription Number 
Total number of prescriptions analyzed 203 
Total number of drugs prescribed 1102 
Average number of drugs per prescription 6 
Number of injections out of total number of drugs prescribed 111 
Total number of anti diabetics out of total number of drugs prescribed 488 
Number of encounters with an antibiotic prescribed 35 
Total Number of Other Drugs  579 
 
Table 10: Description based on drug interaction 
S. No. Severity Frequency Percentage (%) 
1 Major 1 2.63 
2 Moderate 32 84.21 
3 Minor 5 13.16 
Total 38 100 
 
The effectiveness of counseling was analyzed from pre to post tests in 
respect of physical activity, BMI and self scale assessment 
questionnaires. Before the counselling the subjects on physical activity 
was 72(35.47%), whereas after counseling there seems to be a 
significant increase in the number of patients on physical activity as 
127 (62.56%) (table 11). The total number of patients with normal 
BMI has increased after the counseling and the number of patients 
with overweight has decreased after counseling (table 12). 
 
Table 11: Distribution based on physical activity 
S. No. Physical 
activity 
Before After Df X2 Chi square test 
 Frequency % Frequency % Test statistics 
1 Yes 72 35.47 127 62.56 1 63.621 P<0.001 
2 No 131 64.53 76 37.44 
Total 203 100 203 100 
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Table 12: Distribution of subjects according to their pre and post BMI 
S. No. BMI Before After 
Frequency % mean±SD Frequency % mean±SD 
1 <18.5 3 1.5 16.7±0.8 3 1.5 16.4±1.0 
2 18.5-25 78 38.4 22.7±1.6 83 40.9 22.7±1.6 
3 25-30 87 42.9 27.1±1.2 82 40.4 27.1±1.2 
4 30-35 24 11.8 31.4±1.2 26 12.8 31.5±1.2 
5 35+ 11 5.4 38.9±3.6 9 4.4 38.8±3.4 
Total 203 100.0 26.4±4.6 203 100.0 26.2±4.4 
 
All the patients were undergone through the self scale assessment 
questionnaires on good health practices prior to the counseling and 
during the first follow-up. An improvement was observed in respect 
to medication adherence after the counseling [Questions 1, 2 and 3]. 
A positive result was observed in respect to dietary 
recommendations after the counseling [Questions 4 and 5]. A 
positive result was observed in respect to physical activity after the 
counseling [Questions 6]. A greater improvement was observed in 
the monitoring parameters after the counseling [Questions 
7,8,9,10,11 and 12] (table 13). The Wilcoxon rank sign test revealed 
that the adherence improvements was statistically very highly 
significant (P<0.001) (table 14). 
 
Table 13: Self scale assessment questionnaire 
S. 
No. 
Questionnaries Pre counseling Post counseling 
Yes No Yes No 
1 Medication based:  
Do you take your medications on time without missing the 
doses? 
153 (75.37%) 50 (24.63%) 200 (98.52%) 3 (1.48%) 
2 Do you adjust your medication by yourself? 17 (8.37%) 186 (91.63%) 2 (0.99%) 201 (99.01%) 
3 Do you follow any other system of medicines (such as 
Siddha/Ayurvedha/Unani)? 
1 (0.49%) 202 (99.51%) 1 (0.49%) 202 (99.51%) 
4 Diet based:  
Do you sometimes skip your food? 
79 (38.92%) 124 (61.10%) 30 (14.78%) 173 (85.22%) 
5 Do you follow the dietary recommendations given by your 
doctor or dietician or diabetic specialist? 
134 (66.01%) 69 (33.10%) 160 (78.82%) 43 (21.18%) 
6 Physical activity:  
Do you exercise daily? 
72 (35.47%) 131 (64.53%) 127 (62.56%) 76 (37.44%) 
 
7 Monitoring parameters:  
Are you regularly monitoring the blood glucose level with 
care and attention? 
105 (51.72%) 98 (48.28%) 154 (75.86%) 49 (24.14%) 
8 Do you check your eyes at least once in a year? 131 (64.53%) 72 (35.47%) 161 (79.31%) 42 (20.69%) 
9 Do you check your foot regularly? 85 (41.87%) 118 (58.13%) 107 (52.71%) 96 (47.29%) 
10 Are you regularly monitoring other parameters (such as 
Renal Function Test/Complete Blood Count) atleast once in 
six months and Blood Pressure at least weekly/monthly? 
92 (45.32%) 111 (54.68%) 110 (54.19%) 93 (45.81%) 
 11 Are you able to maintain the doctor’s appointments 
recommended for your diabetic treatment? 
99 (48.77%) 104 (51.23%) 127 (62.56%) 76 (37.44%) 
 12 Are you able to cope up with diabetes, with the information 
given by the Physician and Dietician? 
134 (66.01%) 69 (33.99%) 180 (88.67%) 23 (11.33%) 
 
Table 14: Type of adherence from before to after 
Type of adherence Pre-counselling Post counselling Wilcoxon rank sign test 
Frequency % Frequency % Test statistics 
Adherant 62 30.6 100 49.3  
Z=7.874 
P<0.001 
Moderate 80 39.4 91 44.8 
Non Adherant 61 30.0 12 5.9 
Total 203 100 203 100 
  
The patients’ opinion on factors that prevent optimal self-scale 
adherence among the non adherent type 2 diabetes mellitus 
patients were collected. Among them non aware of the 
consequences of missing the dose 61 (19.04%) was the major 
factor reported followed by forgetfulness 60 (18.75%) (table 
15). 
 
Table 15: Non adherence factors 
S. No. Factors Frequency Percentage (%) 
1 Non aware of the consequences of missing the dose 61 19.04% 
2 Forgetfulness 60 18.75% 
3 Self-monitoring of blood glucose was difficult 56 17.5% 
4 Dietary restriction was difficult to maintain 50 15.64% 
5 Lack of time for physical activity 49 15.32% 
6 Lack of financial resources 37 11.57% 
7 Decision to omit due to other reasons 7 2.18% 
*Omission might be due to inconvenience of taking medicines, carelessness, side effects etc. 
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Among the 61 non adherent patients only 52 patients had done the 
HbA1c Tests during both the visits (Pre and Post counseling) among that 
• 44 Patients had a decrease in HbA1C (n=52) 
• 11 Patients had no variation in HbA1C (n=52) 
• 6 Patients has newly done HbAlc after counseling (n=61) (table 
16) 
 
Table 16: HbA1c details of non-adherent patients 
S. No. Non-adherence Pre-counseling Post counseling 
Frequency Percentage Frequency Percentage 
1 HbA1c Done 55 90.2 61 100 
2 HbA1c Not Done 6 9.8 0 0 
Total  61 100 61 100 
 
The effectiveness of counseling was compared in respect of weights, BMI 
and adherence score from before and after counseling. The mean 
weights was 69.9±13.4 and after counseling was 69.4±13.1 Kg. The 
difference of reduction was statistically highly significant (P<0.01). The 
mean BMI before and after were 26.4±4.6 and 26.2±4.4. The reductions 
was statistically highly significant (P<0.01). The before and after 
adherences were 7.5±2.8 and 9.3±1.8. The improvement of adherence 
was statistically very highly significant (P<0.001) (table 17). 
  
Table 17: Comparison of before and after of weights, BMI and questionnaire 
Variables Before After Improved “t” Df Sig 
Mean SD Mean SD Mean SD 
Weights 69.9 13.4 69.4 13.1 0.5 2.3 2.789 202 P=0.006 
BMI 26.4 4.6 26.2 4.4 0.2 0.9 3.247 202 P=0.001 
Adherence 7.5 2.8 9.3 1.8 2.1 1.8 12.614 202 P<0.001 
 
DISCUSSION 
Based on the gender distribution, the study conducted by Javedh 
Shareef et al. [4] found that the male were in greater proportion than 
female. However, the same result was also observed in our study. The 
study conducted by Javedh Shareef et al. [4] states that the age group 
between 51-60 y were at greater proportions than the other age 
groups and also the study conducted by Arif Jemal et al. [6] concluded 
that the study population greater than 60 y were in higher proportions 
compared to other age groups, whereas in our study the age group 
between 55-64years were greater in proportion.  
The study reported by Arif Jemal et al. [6] concluded that patients 
with no family history 182 (92.9%) were at greater proportion than 
patients with family history 14 (7.1%). Henceforth, our study also 
concluded that patients with no family history 134 (66%) was 
greater than patients with family history 69 (34.0%). In accordance 
with the social history distribution, the study conducted by Arif 
Jemal et al. [6] reported that patients who are free of any social 
habits 111 (56.6%) were in higher proportion. Among the patients 
with social habits, chat chewers 82 (41.8%) were predominant. 
Similarly, in our study the patients who are free of any social habits 
were in higher proportion i.e. 175 (86.2%) patients. But in case of 
patients with social habits, the alcoholic users were predominant i.e. 
16 (7.9%) of the study population. The study of Arif Jemal et al. [6] 
reported that forgetfulness 31 (53.45%) was the predominant non 
adherence factor followed by other reasons 23(39.66%) such as side 
effects, poor patient provider relationships etc. 
The study conducted by Sahoo Subhasish et al. [18] reported that 
hypertension 12 (25%) was the major co-morbidity among the 
study population followed by ketosis 11(18.3%). Hence in our study, 
hypertension 75 (36.9%) seems to be the major co-morbidity and 72 
(35.5%) patients reported that they have no co-morbidities. The 
study enclosed by Sahoo Subhasish et al. [19] detected that 6 
moderate, 4 minor and 2 major drug interaction among 60 study 
population, whereas a similar range of severity was observed with 
different class of drugs in our study. 
The study of Mohd Mahmood et al. [19] reported that Biguanides 
(Metformin–57.3%) was the highly prescribed drug in the study 
population, whereas our study reported that the combination of 
Glimepiride+Metformin-(54 in number) as the highly prescribed 
medication followed by second generation sulfonylureas 
(Glimepiride-53 in number). 
The study report of Manjusha S et al. [20] on prescription analysis 
reveals that 105 prescriptions were analyzed, 1281 drugs were 
prescribed and the average number of drugs per prescription was 
12.2. Out of the total drugs prescribed, 171 (13.35%) were anti-
diabetics, 441 (34.43%) were injections and 59 (4.61%) were 
antibiotics.  
Among 203 patients the effectiveness of counseling shows an 
improvement in the adherence rate. The Wilcoxon rank sign test 
revealed that the adherence improvements was statistically very 
highly significant (P<0.001). From the result of the above study 
shows that the patient counseling by the clinical pharmacist place a 
major role in improving the patient’s health status. 
LIMITATIONS 
The study population was lesser in number. The theoretical 
observation of drug interaction was unable to correlate with the 
clinical occurrence due to changes in the time schedule and the cost 
of illness was not involved in the study. 
CONCLUSION 
The results of the current study helps to understand the changes in 
prescription pattern and to identify the drug interactions among the 
prescribed medications. The results also suggests that the patient 
counseling provided by a clinical pharmacist have a greater impact 
in the improvement of patients knowledge about the disease, 
importance of medication adherence and the necessary self care 
practices to be followed in order to maintain a better glycemic 
control and prevention of further complications of the disease.  
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